|
Natrecor in Pulmonary Hypertension Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Natrecor in Pulmonary Hypertension conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Natrecor in Pulmonary Hypertension Clinical research trials and Natrecor in Pulmonary Hypertension healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Natrecor in Pulmonary Hypertension. Natrecor in Pulmonary Hypertension Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Natrecor in Pulmonary Hypertension clinical trial. Participants typically obtain the most effective healthcare available for their Natrecor in Pulmonary Hypertension condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "N" Clinical Trials Conditions > Natrecor in Pulmonary Hypertension  Natrecor in Pulmonary Hypertension
Natrecor in Pulmonary Hypertension
For Condition: Pulmonary Hypertension,Cancer,Lung Disease,Cardiothoracic Surgery
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: The patient population recruited for this study will include patients being considered for cardiothoracic surgery, as treatment for their cancer, who have evidence of PHTN documented by 2-dimensional and Doppler echocardiography (2D-Echo) uncovered during their pre-operative evaluation for malignancy. Eligible patients include those who have normal LV systolic function with PHTN by Doppler echocardiography, defined as a peak tricuspid velocity of 2.5m/sec or greater without evidence of significant valvular disease. An evaluation for pulmonary hypertension by 2D-Echo will have already been completed by the time the patient is considered for this study. Inclusion Criteria: - Age 18 to 85 years old - Pulmonary Hypertension (PHTN) documented by Doppler echocardiography - Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's) - Able to sign informed consent - Patient being considered for Cardiothoracic Surgery Exclusion Criteria: - Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) <90) - Active infection/sepsis - Creatinine greater than 3.0 mg/dl - LV ejection fraction < 40% (must be done with in the last 30 days prior to signing consent) - Significant valvular disease as a cause for the PHTN. - Severe Thrombocytopenia (as defined by platelets less than 20,000) or INR > 1.6 - Hypersensitivity to nesiritide or any of it's components.
Total Enrollment: 20
Location and Contact Information:
Overall Study Official:
DanielLenihan, Study Chair, M.D. Anderson Cancer Center
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting
Additional Information:
Study ID Numbers: 2003-0562;
Study Start Date: January 2004
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00075179
Other Cancer Studies:
1. Natrecor in Pulmonary Hypertension
Related Studies:
Other Cancer Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Natrecor in Pulmonary Hypertension
|
|
|
|
|
|
|
|
